Korean Journal of Geriatrics & Gerontology

Indexed in /covered by CAS, KoreaScience & DOI/Crossref:eISSN 2383-5699   pISSN 1229-6538

Table. 1.

Table. 1.

Landmark clinical trials on treatment of hypertension (age more than 60 years)

SHEP [2] Sys-Eur [3] Sys-China [4] HYVET [5]
Year 1991 1997 1998 2008
Participants 4,736 4,695 2,394 3,845
Age ≥60 y, mean 72 y ≥60 y, mean 70 y ≥60 y, mean 66 y ≥80 y, mean 84 y
BP criteria Systolic BP: 160-219 Systolic BP: 160-219 Systolic BP: 160-219 Systolic BP: 160-199
Active treatment arm Chlorthalidone 12.5-25 mg Nitrendipine 10-40 mg Nitrendipine 10-40 mg Indapamide sustained release 1.5 mg
Add-on therapy Atenolol 25 mg
Reserpine 0.05 mg
Enalapril 5-20 mg
HCTZ 12.5-25 mg
Captopril 12.5-50 mg
HCTZ 12.5-50 mg
Perindopril 2-4 mg
Primary outcome Nonfatal and fatal stroke Nonfatal and fatal stroke Nonfatal and fatal stroke Nonfatal and fatal stroke
Follow-up 4.5 years 2 years 3 years 2.1 years
Major findings 35% reduction in stroke, 25% reduction in coronary artery disease in cardiovascular events 42% reduction in stroke, 26% reduction in cardiac end points, 31% reduction in cardiovascular events 38% reduction in stroke, 37% reduction in cardiovascular events, 39% all-cause mortality 30% reduction in stroke, 23% reduction in cardiovascular mortality, 21% reduction in all-cause mortality

SHEP, systolic hypertension in the elderly program; HYVET, hypertension in the very elderly trial; BP, blood pressure; HCTZ, hydrochlorothiazide.

Korean J Clin Geri 2023;24:100-103 https://doi.org/10.15656/kjcg.2023.24.3.100
© 2023 Korean J Clin Geri